Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Galapagos and Celera Genomics sign gene function analysis agreement

21 Jun 2005 - Galapagos announced that it has entered into a services agreement with Celera Genomics Group, an Applera Corporation business. Under the agreement, Galapagos' services division Galadeno will provide technology and adenoviral reagents enabling Celera to analyze gene function in human cells and validate potential drug targets. Galadeno will receive payments related to its services and technology.
 
Under the terms of the agreement, Galadeno will construct recombinant adenoviruses harboring genes selected by Celera. These custom-made viruses will be used to introduce the genes into various cell types to evaluate their function within biological pathways.